The prevalence of bcl-2, p53, and ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates

Lydia Nakopoulou; Christina Vourlakou; Anastasios Zervas; Αναστασία Τζώνου; Hariklia Gakiopoulou; Meletios A Dimopoulos

doi:10.1016/s0046-8177(98)90225-8

Related publications

Letter2011

Carcinomatous meningitis from transitional cell carcinoma of the urinary bladder.

Efstathios Kastritis, Flora Zagouri, Meletios A Dimopoulos, Papadimitriou Ca

Article1999

Prognostic Significance of p53, bcl-2 and EGFR in Carcinoma of the Endometrium

Pauline Athanassiadou, E. Petrakakou, Anna Liossi, Lydia Nakopoulou, Cherry Zerva, Meletios A Dimopoulos, P. Athanassiades

Article2002

Cell permeable BH3-peptides overcome the cytoprotective effect of Bcl-2 and Bcl-XL

Helena L.A. Vieira, Patricia Boya, Isabelle Cohen, Chahrazed El Hamel, D. Haouzi, Sabine Druillenec, Anne-Sophie Belzacq, Catherine Brenner, Bernárd P. Roques, Guido Guido Kroemer

Article2014

Duration and intensity of tobacco smoking and the risk of papillary and non-papillary transitional cell carcinoma of the bladder

Jerry Polesel, Cristina Bosetti, Matteo Di Maso, Maurizio Montella, Massimo Libra, A. Garbeglio, Antonella Zucchetto, Federica Turati, Renato Talamini, Carlo La Vecchia, Diego Serraino

Article2014

Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer

Yohann Loriot, Pierre Mordant, Delphine Dugué, Olivier Geneste, Andrea Gombos, Paule Opolon, Jean‐François Guégan, Jean‐Luc Perfettini, Alain Pierré, L. Kraus Berthier, Guido Guido Kroemer, Jean‐Charles Soria, Stéphane Depil, Éric Deutsch